GFS784 / GenFleet Therap - LARVOL DELTA

GFS784, a next-generation ADC with a novel panRAS(ON) inhibitor payload (AACR 2026) - "Compared with combination therapy using Cetuximab and RMC-6236 at clinical equivalent doses, GFS784 demonstrated comparable efficacy but better tolerability in CDX mice. GFS784 has a satisfactory preclinical profile as an ADC candidate. GFS784 is effective in CDX models resistant to DXd ADC or Osimertinib, suggesting the potential as a next-generation ADC and an alternative solution for TKI resistance. Therefore, GFS784 provides a promising solution for treating RAS mutant or EGFR-altered tumors and a further clinical investigation is warranted."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

GFS784, a functional and synergistic conjugate (FAScon) with novel pan-RAS(ON) payload [WITHDRAWN] (AACR 2025) - "Abstract is embargoed at this time."

Late-breaking abstract • Oncology

GenFleet Therapeutics…is pleased to announce that the Company will exhibit preclinical research data of three compounds - GFH276 (non-degrading molecular glue), GFS784 (novel antibody-drug conjugate linking functional antibody with synergistic targeted payload) and GFH603 (molecular glue-like covalent allosteric activator) - at the poster presentation of the 2026 AACR Annual Meeting (HKEXnews)

Preclinical • Oncology